Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists
- 1 February 1996
- journal article
- Published by Elsevier in Neuropeptides
- Vol. 30 (1) , 73-79
- https://doi.org/10.1016/s0143-4179(96)90058-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Molecular pharmacology of V1a vasopressin receptorsGeneral Pharmacology: The Vascular System, 1995
- Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by l-amino acidsBiochemical Pharmacology, 1994
- Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressinInternational Journal of Peptide and Protein Research, 1992
- Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressinJournal of Medicinal Chemistry, 1990
- Conformational and Structural Considerations in Oxytocin-Receptor Binding and Biological ActivityAnnual Review of Pharmacology and Toxicology, 1990
- A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activityJournal of Medicinal Chemistry, 1989
- No requirement of cyclic conformation of antagonists in binding to vasopressin receptorsNature, 1987
- Chapter 16 Neurohypophyseal hormone receptor systems in brain and peripheryPublished by Elsevier ,1987
- Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(.beta.-mercapto-.beta.,.beta.-pentamethylenepropionic acid), 2-D-isoleucine, 4-valine]arginine-vasopressin at position 4Journal of Medicinal Chemistry, 1984
- [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressinJournal of Medicinal Chemistry, 1980